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Aims and scope
Over the last six years, the use of targeted agents has revolutionised the treatment of
metastatic renal cell carcinoma (mRCC) and dramatically improved outcomes for patients.
Multiple effective ﬁrst- and second-line agents are now available or are in development,
raising key questions and new challenges around the long-term management of mRCC.
These topics were the focus of a Pﬁzer meeting held at the 7th European International
Kidney Cancer Symposium (EIKCS) in Vienna (4−5 May 2012), where leading European
oncology experts discussed recent advances and ongoing issues in mRCC clinical practice.
‘It is important for clinicians who see large numbers of patients with this rare disease to get together
and share their experience and observations, for the beneﬁt of those who only see few patients in
their practice’, said Professor Manuela Schmidinger, Chair of the meeting.
This report offers an overview of the critical evidence and the issues of long-term mRCC
management debated at the meeting. It also presents key conclusions from the recently
launched report ‘Europe 2012: is kidney cancer management at a crossroad?’, written by
a selected panel of European kidney cancer experts to highlight current barriers to the
optimal treatment of mRCC patients and the development of solutions to address these.
© 2012 Elsevier Ltd.
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1. Introduction
The treatment of mRCC has been revolutionised by the
development of targeted therapies that have signiﬁcantly
improved progression free survival (PFS) as well as overall
survival (OS) for patients compared with the previous
standard of care, immunotherapy treatments (Fig. 1).
Targeted agents have revolutionised
patient outcomes in mRCC
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Fig. 1 – Targeted agents have revolutionised patient
outcomes in mRCC. In the past, when immunotherapy was
the standard of care, only a minority of patients (~5%)
derived beneﬁt from it in terms of long-term outcome.
Once the disease progressed, there was no other treatment
left for those patients. Today, based on an improved
understanding of the molecular characteristics of this
disease, multiple targeted agents are available, which
have been shown to beneﬁt the majority of patients, in
terms of response rates and extension of overall survival.
aMotzer and Molina 1, 2009. Slide courtesy of Manuela
Schmidinger, 2012.
Long-term survival is now becoming a realistic goal and
as a consequence, the clinical focus is shifting towards
maximising the long-term beneﬁts of such therapies by
optimising the selection and management of treatment
for each individual patient.
On this basis, the Pﬁzer sponsored meeting at the
7th European International Kidney Cancer Symposium in
Vienna (4−5 May 2012) aimed to review the key factors
that should guide treatment selection and effective
management of the available agents in both ﬁrst- and
second-line treatment settings.
Achieving long-term survival requires careful selection
of treatment for each individual patient. What are the
most important factors that should guide clinicians in
the selection of the most appropriate therapy?
Focusing on optimal ﬁrst-line treatment, Martin Gore
and Manuela Schmidinger, from the Royal Marsden
Hospital (London) and the Medical University of Vienna,
respectively, highlighted the critical importance of
efﬁcacy and clinical experience as the key drivers of
treatment selection. In addition, they reviewed evidence
of how practical and effective therapy management
strategies are equally critical to ensuring optimal
clinical beneﬁt and envisaged the use of certain clinical
biomarkers to predict treatment efﬁcacy and further
optimise long-term clinical outcomes.
Based on data from currently available agents and
results from ongoing studies, Camillo Porta from the
IRCCS San Matteo University Hospital Foundation (Pavia)
reviewed ﬁrst-line treatment options for difﬁcult-to-treat
patients, such as those with a poor prognosis or non-
clear cell histology.
Finally, Sylvie Ne´grier from the University of Lyon
illustrated second-line treatment selection criteria in
mRCC patients and discussed the beneﬁts that im-
plementation of rational sequencing approaches can
provide to achieving a long-term continuum of care.
As important as treatment selection is ensuring that
patients have equal access to the new treatments for
mRCC across Europe. In November 2011, an independent
panel of European experts in kidney cancer met to
discuss the major barriers currently involved in the
management of mRCC across Europe. Optimal treatment
sequencing, equal access to treatments and education
of healthcare professionals emerged as key challenges.
Following their meeting, the group published a report
entitled ‘Europe 2012: is kidney cancer management
at a crossroad?’ (Fig. 2), with the aim of increasing
Fig. 2 – ‘Europe 2012: is kidney cancer management at a
crossroad?’
This report is available at www.lh-nierenkrebs.org
the understanding of these challenges, and facilitating
improvements in patient treatment, outcomes and
experience.
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Agent n
Median PFS
(months)
Median OS
(months) ORR (%)
Sunitinib vs IFN-αa 750 11 vs 5
p<0.001
26.4 vs 21.8
p=0.051
47 vs 12
p<0.001
Bevacizumab + IFN-α vs IFN-αb,c 649 10.2 vs 5.4
p<0.0001
23.3 vs 21.3
p=0.1291
31 vs 13
p=0.0001
Bevacizumab + IFN-α vs IFN-αd,e 732 8.5 vs 5.2
p<0.0001
18.3 vs 17.4
p=0.069
26 vs 13
p<0.0001
Pazopanib* vs placebof,g 435 11.1 vs 2.8
p<0.0001
22.9 vs 20.5†
p=0.224
30 vs 3†
p<0.001
Poor-risk patients
Temsirolimus vs IFN-αh‡ 626 5.5 vs 3.1
p<0.001
10.9 vs 7.3
p=0.008
8.6 vs 4.8
NS
*Conditionally approved; †Includes cytokine refractory and treatment-naïve patients; ‡Poor-risk patients (modified
MSKCC criteria)
Recommended targeted agents for first-
line treatment: Results from pivotal trials
Fig. 3 – Recommended targeted agents for ﬁrst-line treatment: results from pivotal trials. Targeted agents enabled signiﬁcant
improvements in progression free survival compared to immunotherapy, which used to be the standard of care. aMotzer
and Molina 1, 2009; bEscudier et al. 2, 2007; cEscudier et al. 3, 2010; dRini et al. 4, 2008; eRini et al. 5, 2010; f Sternberg et al. 6,
2010; gSternberg et al. 7, 2010; hHudes et al. 8, 2007. Slide courtesy of Martin Gore, 2012.
2. Efﬁcacy and experience: key considerations in
ﬁrst-line treatment selection
Martin Gore, Royal Marsden Hospital, London, UK
Martin Gore is the Medical Director of the
Royal Marsden Hospital and Professor of Cancer
Medicine at the Institute of Cancer Research in
London. His main research interests include the
development of novel therapeutics in ovarian
cancer, melanoma and renal cell carcinoma,
particularly in the area of biologics, gene therapy
and novel targeted agents. He is a Medical Advisor to the US
Kidney Cancer Association and co-founder of the annual European
International Kidney Cancer Symposium.
Manuela Schmidinger, Department of Oncology,
Medical University of Vienna, Vienna, Austria
Manuela Schmidinger is a Medical Oncologist and
Professor of Medicine at the University of Vienna.
She is currently Programme Director for mRCC,
leading the research programme in the ﬁeld of
kidney cancer and the care of patients with RCC.
Her research interests include prognostic factors
and treatment in RCC, mechanisms of tyrosine kinase inhibitor-
related side effects and management of side effects.
What are the key drivers to deciding which agent to use
in the ﬁrst-line treatment of mRCC? Martin Gore opened
his presentation by stating that, for most oncologists, the
key driver is clinical efﬁcacy, represented by improved
tumour control and prolonged survival.
A wealth of randomised clinical trials investigating
the efﬁcacy of targeted agents in the last few years has
provided the basis for the creation of ﬁrst-line treatment
algorithms (Fig. 3).
Guidelines from the European Society for Medical
Oncology (ESMO) and the European Association of
Urology (EAU) indicate sunitinib, bevacizumab+ IFN-a
and pazopanib (which is conditionally approved in the
European Union) as the most efﬁcacious treatments
for favourable/intermediate-risk patients, whereas tem-
sirolimus is recommended as the current standard of
care for poor-risk patients. 9,10
A number of new studies will release results in the
next 12−18 months and add information on the efﬁcacy
and toxicity of targeted agents. First, a phase III study
of tivozanib in ﬁrst- or second-line settings (TIVO-1,
n=517), 11 in which the primary endpoint has been
reached, showed statistically signiﬁcant improvement
in PFS with tivozanib compared with sorafenib. 12 The
COMPARZ study (n=927), 13 a non-inferiority trial of
pazopanib versus sunitinib in previously untreated
mRCC patients, will provide data in relation to toxicity,
although, being a non-inferiority study, it will not provide
deﬁnitive data on the efﬁcacy of pazopanib in relation to
sunitinib. Another upcoming phase III study, PISCES, 14
has compared continuous dosing of pazopanib with
sunitinib given with a 50mg 4/2 schedule (4 weeks
on treatment followed by 2 weeks off treatment) over a
ten week period, assessing patient preference based on
toxicity proﬁle (n=169). Finally, the AGILE phase III study
(n=492), 15 comparing axitinib with sorafenib, is expected
to produce interesting information on the use of these
two agents in both ﬁrst- and second-line settings.
With a growing number of available ﬁrst-line targeted
agents, how do clinicians achieve optimal therapy?
Professor Gore emphasised that the achievement of long-
term survival is the combined result of optimal dosing
schedules, appropriate management of side effects and
treatment duration (Fig. 4).
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Q: How can we optimise outcomes and prolong
survival with current first-line therapies?
 A: Effective therapy management
Dosing
Duration of
treatment
AE management
Optimum
Efficacy
Fig. 4 – How can we optimise outcomes and prolong
survival with current ﬁrst-line therapies? Optimal therapy
is the result of (i) optimal treatment dosing; (ii) effective
management of side effects; (iii) optimal treatment
duration. Schmidinger M, Arnold D, Szczylik C, Wagstaff J,
Ravaud A. 16 Optimizing the use of sunitinib in metastatic
renal cell carcinoma: an update from clinical practice.
Cancer Invest 2010;28:856−64. Slide courtesy of Martin Gore,
2012.
‘The most critical issue in mRCC clinical practice is the active
management of side effects’, commented Professor Gore.
‘Physicians must carefully assess each individual patient for
baseline comorbidities, pre-empt side effects by treating them
before the cancer therapy starts, and teach their patients how
to best manage the toxicity so that they can achieve long-term
results’. In the case of sunitinib, recent studies indicate
that dosing adjustments that allow prolonged treatment
duration are associated with improved responses. 17
This underlies the importance of maintaining long-
term exposure to targeted agents that show activity in
order to obtain long-term outcomes. Long-term exposure
to targeted agents in patients who experience clinical
beneﬁt was recently investigated in a multicentre,
retrospective analysis looking speciﬁcally at a group of
mRCC patients who obtained complete remission (CR)
during treatment with tyrosine kinase inhibitors (TKIs)
sunitinib or sorafenib. 18 The majority of CR cases were in
patients treated with sunitinib (n=59, 92%) and the study
shows that CR was obtained after at least 12.6 months
of treatment (TKI treatment alone), or even longer for
patients receiving TKI therapy plus local treatment. 18
When looking at the most frequent side effects
associated with targeted agents, there is a real com-
monality of adverse events (AEs) shared by the ﬁrst-
line agents sunitinib, 1 bevacizumab, 2,5 pazopanib 6 and
temsirolimus 8 (Fig. 5). These are fatigue, hypertension,
diarrhoea and gastrointestinal disorders. Emerging data
show that some of the AEs appear to behave as clinical
Most common AEs ( 20%) reported with≥
targeted agents for first-line treatment of mRCC
 Most are mild-to-moderate in intensity
 Manageable with therapy management strategies
HFS, hand–foot syndrome
Pazopanibd
Diarrhoea, hypertension, hair colour changes,
nausea, anorexia, vomiting
Bevacizumab/IFN-αb,c
Anorexia, fatigue/asthenia, haemorrhage, hypertension,
influenza-like illness, headache, diarrhoea
Temsirolimuse
Asthenia, anaemia, rash, gastrointestinal disorders, oedema,
metabolic disorders, dyspnoea, cough, bacterial infections
Sunitiniba
Fatigue, gastrointestinal disorders, decreased appetite,
hypertension, HFS, skin discolouration, mucosal inflammation
Fig. 5 – Most common side effects of ﬁrst-line targeted agents. The most common adverse events (>20%) reported with
all targeted agents for ﬁrst-line treatment of mRCC are gastrointestinal disorders, hypertension and fatigue. aMotzer and
Molina AM 1, 2009; bRini et al. 5, 2010; cEscudier et al. 2, 2007; dSternberg et al. 6, 2010; eHudes et al. 8, 2007. Slide courtesy
of Martin Gore, 2012.
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Summary Box 1
• The development of targeted agents has revolutionised the treatment of mRCC
• Efﬁcacy and clinical experience are both key drivers of treatment selection in the ﬁrst-line setting
• It is important that targeted agents are effectively managed to obtain optimal clinical outcomes by:
√
optimising dosing
√
maximising treatment duration
√
effective management of adverse events
• In the future, certain clinical biomarkers may be used to predict treatment efﬁcacy, and thus further optimise
clinical outcomes
biomarkers for tumour control as well as OS, in particular
hypertension, 19 but also myelosuppression, 20 hand–
foot syndrome, 21 and fatigue. 22 PFS was shown to be
longer in mRCC patients with hypertension treated with
sunitinib. 19 Interestingly, the same study also showed
that management of hypertension did not affect the
efﬁcacy of the treatment. 19 These clinical markers are
awaiting validation, but in the future they may be used to
predict treatment efﬁcacy and allow further optimisation
of clinical outcomes.
Along with efﬁcacy, it is important not to under-
estimate the role of clinical experience when making
appropriate treatment decisions. Professor Schmidinger
emphasised that experience plays a critical role when,
in addition to Memorial Sloan Kettering Cancer Cen-
tre (MSKCC) risk criteria, 23 clinicians need to take into
account factors that are individual to each patient with
the aim of individualising treatment and improving
outcomes. These factors include patient lifestyle, quality
of life, expectations of therapy, as well as ‘real
world’ clinical and disease-related factors, such as
comorbidities, symptoms, and aggressiveness of the
disease.
Since the ﬁrst mRCC targeted agents were introduced
back in 2006, growing clinical experience has become
crucial when clinicians have to decide when to start
ﬁrst-line treatment, which agent to select, and when
to implement effective therapy management, resulting
in optimal patient outcome. ‘Current treatment guidelines
do not tell us when to commence targeted therapy’,
commented Professor Schmidinger, ‘clinical experience
allows us to establish the optimal time for each individual
patient’.
The case of a 44-year-old patient diagnosed with
RCC served to illustrate the importance of clinical
experience in ﬁrst-line treatment selection. The patient
was diagnosed with primary metastatic disease in
9 different sites and classiﬁed as being at an intermediate
risk level, according to MSKCC criteria. 23 Based on
clinical experience-related considerations, the patient
underwent nephrectomy and started therapy with
sunitinib (50mg, schedule 4/2), which enabled a PFS of
more than 16months and CR ofmostmetastatic lesions.
In conclusion, appropriate therapy management is
largely based on real-life clinical experience. ‘Management
of speciﬁc side effects can be challenging for the patients’, said
Professor Schmidinger ‘but clinical experience now enables
clinicians to avoid discontinuation of treatment by controlling
most side effects with appropriate supportive and prophylactic
measures, so as to achieve long-term outcomes’. Importantly,
improved outcomes observed in phase III clinical trials
of targeted agents are reproducible in the ‘real world’
clinical practice, where years of clinical experience can
now be used to beneﬁt the real patient population.
3. Difﬁcult-to-treat mRCC patients: available
ﬁrst-line options and remaining questions
Camillo Porta, IRCCS San Matteo University Hospi-
tal Foundation, Pavia, Italy
Camillo Porta is a Senior Staff Member of the
Unit of Medical Oncology at the IRCCS San
Matteo University Hospital Foundation in Pavia
and Adjunct Professor of Medical Oncology at
the School of Biotechnology and the Postgraduate
Schools of Medical Oncology and General Surgery
at the University of Pavia. His clinical interests include clinical trials
in advanced kidney cancer and hepatocellular carcinoma, and the
development of new targeted agents.
Optimal treatment options for poor-risk patients, or
those with non-clear histologies, are often not widely
known or are under-investigated. Temsirolimus is the
only agent that has been investigated in a large poor-risk
patient population (n=626), demonstrating impressive
beneﬁts in both PFS and OS 8 (Fig. 6).
Approximately 20% of all patients with mRCC are
categorised as poor-risk according to the MSKCC
criteria, 23 and temsirolimus is currently the only agent
recommended for ﬁrst-line treatment in poor-risk mRCC
patients (ESMO/EAU guidelines), based on the results
of the phase III ARCC clinical trial. 8 The ARCC study
showed a 49% increase in median OS with temsirolimus
compared with IFN-a, 8 demonstrating that temsirolimus
can signiﬁcantly improve the OS in patients with such
6 ejc supplements 10, no. 2 (2012) 1–11
Phase III evidence: Temsirolimus is efficacious
in poor-risk patients with advanced RCC
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Fig. 6 – Phase III evidence: temsirolimus is efﬁcacious in poor-risk patients with advanced RCC. The ARCC study showed a
49% increase in median overall survival with temsirolimus compared with IFN-a. Slide courtesy of Camillo Porta, 2012, from
Hudes G, Carducci M, Tomczak P, et al.; Global ARCC Trial. 8 Temsirolimus, interferon alfa, or both for advanced renal-cell
carcinoma. N Engl J Med 2007;356:2271−81. © Massachusetts Medical Society.
Summary Box 2
• Temsirolimus is the only agent to date to demonstrate a signiﬁcant improvement in median overall survival in
the poor-risk patient population
• Ongoing studies will help to further optimise ﬁrst-line treatment in these difﬁcult-to-treat patients
• Promising clinical biomarkers await further development and validation
poor prognosis. The efﬁcacy of other targeted agents
in these patients remains largely unproven, although
moderate PFS increases have been reported in a small
sample population of poor-risk patients following ﬁrst-
line treatment with sunitinib. 24
As discussed for intermediate-risk patients, the
identiﬁcation and validation of biomarkers to predict
treatment outcomes could also help the implementation
of individualised therapy for poor-risk patients. As yet,
a few promising clinical biomarkers predictive of
temsirolimus efﬁcacy have been reported, including
speciﬁc molecular components of the mTOR pathway, 25
as well as levels of serum LDH, 26 cholesterol 27 and
pneumonitis 28. ‘It is imperative to concentrate forces into the
identiﬁcation of predictive markers’, commented Dr Porta.
‘The ability to predict efﬁcacy of treatment would not only limit
patient exposure to unnecessary toxicity, but would also enable
clinicians to provide patients with more reliable information on
the potential beneﬁt of a given treatment’.
4. Optimal sequencing strategies for achieving
long-term survival
Sylvie Ne´grier, University of Lyon 1 and Le´on
Be´rard Cancer Centre, Lyon, France
Sylvie Ne´grier is Professor of Medicine at the
University of Lyon and a Medical Oncologist
and Director of the Le´on Be´rard Cancer Centre.
Her main research interest is the treatment of
malignant melanoma and mRCC. She is a member
of many organisations, including the European
Society for Medical Oncology and is particularly involved with Groupe
d’Etudes Franc¸ais des Cancers du Rein, where she has acted as
principal investigator for several multicentre trials investigating the
use of immunotherapy and targeted therapies in solid tumours.
For most mRCC patients, resistance to ﬁrst-line therapy
eventually develops, leading to disease progression. At
that stage, clinicians face the very important question of
when is the right time to start second-line treatment.
Professor Ne´grier explained that ‘disease progression’
includes a wide range of clinical scenarios, and therefore
ejc supplements 10, no. 2 (2012) 1–11 7
AXIS: Axitinib significantly prolonged
PFS vs sorafenib
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Fig. 7 – Axitinib signiﬁcantly prolonged progression free survival when compared with sorafenib. The AXIS trial investigated
the efﬁcacy of the VEGFR inhibitor axitinib versus sorafenib in 723 patients who had previously received sunitinib as ﬁrst-
line treatment. Slide courtesy of Sylvie Negrier, 2012, from The Lancet, Vol. 378, Rini BI, Escudier B, Tomczak P, et al. 40,
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial,
Pages 1931−9, Copyright 2011, with permission from Elsevier.
clinicians need to use a combination of pathological
data, clinical assessment and patient individual factors
to decide whether disease progression has occurred and
a second-line treatment is needed.
Recent evidence suggests that, whereas Response
Evaluation Criteria In Solid Tumours (RECIST) are valid
to compare drugs in clinical trials and identify primary
resistance to targeted therapies, they are not sufﬁcient to
deﬁne disease progression in real-life clinical practice, 29
or to evaluate the efﬁcacy of anti-angiogenic therapies
that induce necrosis often without changes in tumour
size. 30 Recently developed alternatives to RECIST include
functional imaging techniques and dynamic contrast-
enhanced ultrasonography, 30 which should allow more
precise monitoring of disease progression.
Determining optimum treatment sequencing may help
patients to overcome resistance that develops after treat-
ment with ﬁrst-line agents. Therapy sequencing allows
full dosages of targeted agents to be administered, 31
and to avoid toxicity issues that have been observed
in combination therapies. 32,33 ‘Optimal sequences have not
been identiﬁed yet’, commented Professor Ne´grier, ‘but a
number of ongoing trials investigating different sequence com-
binations will provide results over the next two years that will
hopefully enable clinicians to apply optimal sequencing in real-
life clinical practice’. Optimal sequencing strategies also
involve ensuring prolonged treatment duration for ﬁrst-
line treatments that demonstrate activity. ‘It is critical to
properly manage treatment-associated toxicity to prevent early
switching from the most active ﬁrst-line therapies and fully
exploit their potential’, explained Professor Ne´grier.
In therapy sequencing, there is no evidence that
a change in mechanism of action following anti-
angiogenic targeted agents would result in better
outcomes compared with maintaining VEGFR inhibition
in the second-line setting. Not only has cross-resistance
not been observed with the sequential use of VEGFR
inhibitors, but clinical data and meta-analyses indicate
that mRCC patients remain sensitive to VEGFR inhibition
following ﬁrst-line anti-angiogenic therapy and toxicity
is attenuated. 34−39
So far, the only recommended (ESMO/EAU guidelines)
second-line treatment option following VEGFR inhibitors
is the mTOR inhibitor everolimus. 9,10 However, the
VEGFR inhibitor axitinib has recently been shown in the
AXIS study 40 to signiﬁcantly improve PFS in a second-line
setting following sunitinib, when compared to sorafenib
in patients with treatment-refractory mRCC (n=723)
(Fig. 7).
AXIS is the ﬁrst head-to-head trial of targeted agents
in second-line mRCC and its results support sequencing
of TKI to TKI. Axitinib is currently being evaluated by
the European Medicines Agency (EMA) as a second-
line treatment for mRCC. It is currently considered a
8 ejc supplements 10, no. 2 (2012) 1–11
Summary Box 3
• Despite the beneﬁts observed with the currently available ﬁrst-line agents, resistance to targeted agents
eventually develops
• A rational approach to sequencing targeted agents may be used to provide patients with a long-term continuum
of care
• Selecting the most appropriate agent to use in a second-line setting should be based on robust clinical evidence
• AXIS, a study that investigates the efﬁcacy of the VEGFR inhibitor axitinib in a second-line setting, is the ﬁrst
head-to-head trial of targeted agents in second-line mRCC
√
Axitinib signiﬁcantly improved progression free survival when compared with sorafenib
√
Axitinib is currently being evaluated by the European Medicines Agency (EMA) as a second-line treatment
for mRCC
category 1 recommendation in patients who have failed
at least one systemic therapy by the 2012 National
Comprehensive Cancer Network (NCCN) Guidelines in
the United States. 41
The current availability of multiple efﬁcacious targeted
agents means that therapeutic options still exist for
patients who have failed ﬁrst- or second-line therapy.
Amongst sequential phase II/III trials that investigated
third-line treatment options, RECORD-1 (n=390) identi-
ﬁed everolimus as an active treatment. 42−44 Most of the
patients in this study (79%) had received two or more
prior therapies and almost a third (26%) had previously
received two VEGFR inhibitors. 44,45 Therefore, these
results may provide clinicians with a valid evidence-
based option to improve outcomes of mRCC patients in
third-line settings.
5. Europe 2012: is kidney cancer management at
a crossroad?
Bernard Escudier, Institut Gustave Roussy, Ville-
juif, France
Bernard Escudier is the Head of the Im-
munotherapy Unit in the Department of Medical
Oncology at the Institut Gustave Roussy in
Villejuif. He is the President of ‘ARTuR’, the
French association on renal tumours, and the
Head of the French Group of Immunotherapy.
His research interests are in the ﬁelds of renal
carcinoma, melanoma, immunotherapy, as well
as the development of new treatment strategies
(anti-angiogenic drugs, gene therapy). Professor
Escudier is the principal investigator of many clinical trials in renal
cell cancer.
A key message emerging from the Pﬁzer sponsored
meeting held at the 7th EIKCS in Vienna this year is
that new targeted treatments and improved survival
rates are not only revolutionising mRCC treatment but
are also putting forward new questions and challenges
to healthcare professionals (HCPs) and kidney cancer
patients.
The ‘Europe 2012: Is kidney cancer management at
a crossroad?’ report was developed by an independent
expert panel of leading kidney cancer specialists from
ﬁve European countriesA, following a meeting held
in Paris at the end of 2011. The meeting aimed to
identify challenges and other critical barriers to optimal
mRCC treatment, as well as to propose solutions to
improve patient and clinician experience in managing
this condition. A number of key issues were identiﬁed:
guidance to HCPs on new treatment and therapy
management strategies; consistent treatment guidelines;
equal access to new treatments for patients across
Europe and, ﬁnally, acknowledgement of the role of
patients in optimising therapy outcomes.
5.1. Treatments
The availability of an increasing number of treatment
options for kidney cancer means that more guidance
is needed for HCPs on how best to optimise treatment
through appropriate therapy management. ‘mRCC is a
relatively rare cancer, and most oncologists outside of expert
centres will only see a small number of mRCC patients in
a year’, said Professor Bernard Escudier. ‘There is a need
for more HCPs to gain the necessary experience in using
the new targeted agents and to address the challenge of
educating patients in a new way of treating cancer as a chronic
disease that can be controlled by selecting the most appropriate
A Expert panel:
Bernard Escudier, Head of the Immunotherapy Unit, Institut Gustave Roussy, France
Emilio Esteban Gonza´lez, Laboratory of the University Institute of Oncology, Spain
Michael Staehler, Ludwig Maximilians University, Germany
Sergio Bracarda, Ospedale San Donato, Arezzo, Italy
Tom Powles, Consultant Oncologist, Barts and the London, UK
Berit Eberhardt-Wetherington, Das Lebenshaus, Germany
Markus Wartenberg, Das Lebenshaus, Germany
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treatment over time’, he added. More guidance is therefore
needed for HCPs on how to optimise treatment duration
and sequencing in order to achieve long-term results for
their patients.
5.2. Guidelines and healthcare professional experience
Guidelines play a key role in maintaining high standards
of patient care. However, anecdotal evidence has shown
that currently available mRCC guidelines are not being
widely used by HCPs and tend not to reﬂect real-
life clinical practice. ‘It would be expected from academic
institutions or drug companies to create widely accepted
and comprehensive treatment guidelines, to ensure that the
standard of care at non-expert centres is comparable to
that at expert institutions’, commented Professor Escudier.
There is also an urgent need to improve the education
of general oncologists, as well as other HCPs involved
in oncology (e.g. nurses and radiotherapy specialists).
Whereas it will be possible to answer many speciﬁc
questions with new and improved clinical studies,
experience in managing mRCC will be the most
important learning tool for HCPs.
5.3. Access to new treatments and patient empowerment
Access to new treatments for mRCC varies considerably
throughout Europe compared to the rest of the world.
It is imperative that clinicians have access to the most
promising new agents to enhance patients’ likelihood
of survival. For a relatively rare cancer such as kidney
cancer, it is currently still being debated whether patients
across Europe should be referred only to expert centres
or whether high quality clinical experience should be
spread to non-expert centres too. Increasing the number
of specialised centres across Europe would help to reduce
waiting times and the need to travel long distances for
treatment. As the prognosis of mRCC patients improves,
the number of people living with treatment side effects
is increasing, and patients need to be given the right
support to help recognise and communicate about their
side effects to ensure they achieve optimal efﬁcacy.
Patient advocacy groups are vital in supporting the
speciﬁc needs of mRCC patients, who have access to
support groups and online information.
5.4. Conclusions and call to action
Recognising the need to challenge the way clinicians
manage mRCC therapy to further improve the outcome
for patients, the authors of the report developed a ‘Call to
Action’ that addresses four main areas of unmet needs:
• Improve levels of education and disease awareness
among all HCPs involved with mRCC management
throughout Europe
• Ensure research and development into new targeted
therapies and associated biomarkers is prioritised to
establish optimal treatment sequencing for mRCC
• Eliminate the disparity in survival rates seen across
Europe by ensuring all patients have access to the
appropriate mRCC medicines across multiple lines of
treatment
• Give more time and emphasis to the management of
mRCC as a chronic disease to support people living
with side effects as survival rates increase
6. Conclusions
• Efﬁcacy and clinical experience are key drivers of
treatment selection in a ﬁrst-line setting.
• Targeted agents need to be effectively managed to
obtain optimal clinical outcomes.
• Clinical biomarkers are under evaluation to under-
stand their potential role in predicting treatment
efﬁcacy.
• Temsirolimus is the only agent to date to demonstrate
a signiﬁcant improvement in median overall survival
in the poor-risk patient population.
• A rational approach to sequencing targeted agents
may be used to provide patients with a long-term
continuum of care; robust clinical evidence should
guide selection of the most appropriate second-line
agents.
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